Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Inhibitors of the vascular endothelial growth factor (VEGF) pathway frequently induce hypertension when used to treat patients with advanced renal cell carcinoma (RCC). This analysis characterizes hypertension and hypertension-related events in patients treated with the VEGF pathway inhibitors axiti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Target Oncol
Main Authors: Rini, Brian I., Quinn, David I., Baum, Michael, Wood, Laura S., Tarazi, Jamal, Rosbrook, Brad, Arruda, Lillian Shahied, Cisar, Laura, Roberts, W. Gregory, Kim, Sinil, Motzer, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2014
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4363524/
https://ncbi.nlm.nih.gov/pubmed/24595903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-014-0307-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados